Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

2020

Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, et al. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020;78(4):637-639.
Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.
Zhou P, Yan F. CRL4 Ubiquitin Pathway and DNA Damage Response. Adv Exp Med Biol. 2020;1217:225-239.
Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, et al. DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051-1063.
Rubinstein MM, Goss C, Avecilla ST, Dubé GP, Riely GJ, Mones JV. Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2020;8(2):289-292.
Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, et al. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell Rep. 2020;30(3):755-770.e6.
Fiore D, Cappelli LV, Zumbo P, Phillips JM, Liu Z, Cheng S, et al. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. Cancers (Basel). 2020;12(6).
Pisapia DJ, Ohara K, Bareja R, Wilkes DC, Hissong E, Croyle JA, et al. Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. Acta Neuropathol Commun. 2020;8(1):80.
De Piano M, Manuelli V, Zadra G, Otte J, Edqvist P-, Pontén F, et al. Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases. Oncogene. 2020;39(18):3666-3679.
Kim D, Viswanathan K, Goyal A, Rao R. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 2020;128(4):269-277.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700